全球疫苗生产市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

疫苗生产市场分析

由于传染病发病率上升和大流行病的持续威胁，全球对疫苗的需求不断增加，疫苗生产市场正在经历显着增长。最近的发展，特别是应对 COVID-19 大流行的发展，加速了疫苗技术的进步，包括 mRNA 和病毒载体平台，提高了疫苗开发的效率和速度。市场的主要参与者正在大力投资研发，旨在创新和生产多种疫苗以针对各种疾病，包括流感、HPV 等。此外，随着政府和卫生组织优先考虑疫苗接种计划，发展中地区对免疫计划的日益关注正在扩大市场机会。因此，在技术进步、医疗支出增加以及对疫苗在公共卫生中重要性的认识提高的推动下，疫苗生产市场有望实现强劲增长。

疫苗生产市场规模

2023 年全球疫苗生产市场规模价值 510.7 亿美元，预计到 2031 年将达到 894.0 亿美元，2024 年至 2031 年预测期内的复合年增长率为 7.25%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

疫苗生产市场趋势

“ mRNA技术的兴起与个性化免疫”

The vaccine production market is witnessing dynamic trends fueled by ongoing advancements in technology and a heightened focus on public health. One notable trend is the increasing adoption of mRNA vaccine technology, which gained prominence during the COVID-19 pandemic due to its rapid development and efficacy. This innovation allows for quicker response times to emerging infectious diseases and enhances the ability to create targeted vaccines for various pathogens. In addition, there is a growing emphasis on personalized vaccines, utilizing genetic information to tailor immunizations to individual patients for improved outcomes. As a result, the vaccine production landscape is evolving, with companies investing in research and development to harness these innovative technologies, ensuring a more efficient and effective approach to global vaccination efforts.

Report Scope and Vaccine Production Market Segmentation 

Vaccine Production Market Definition

Vaccine production refers to the process of developing, manufacturing, and distributing vaccines that are designed to induce immunity against specific infectious diseases. This process involves several critical stages, including the identification of pathogens, selection of appropriate antigens, formulation of vaccine components, and rigorous testing for safety and efficacy. Vaccines can be produced using various technologies, such as inactivated or attenuated pathogens, recombinant DNA technology, and mRNA platforms. The production process also includes quality control measures to ensure that the final product meets regulatory standards before it is made available for public use.

Vaccine Production Market Dynamics

Drivers

• Increasing Prevalence of Infectious Diseases

The increasing prevalence of infectious diseases has significantly heightened the global demand for vaccines as a critical tool for protecting public health, making it a key driver in the vaccine production market. Recent outbreaks of viruses such as COVID-19, influenza, and measles have underscored the urgency for effective vaccination strategies. For instance, the COVID-19 pandemic led to unprecedented vaccine development efforts, resulting in multiple vaccines being authorized for emergency use within a year, showcasing the importance of rapid response in public health. Similarly, seasonal influenza continues to affect millions worldwide, emphasizing the need for annual vaccinations to prevent severe illness. The resurgence of measles, once considered eliminated in many regions, further highlights the necessity for comprehensive vaccination programs. As these infectious threats persist, the demand for vaccines remains crucial for safeguarding communities and promoting overall health, driving growth in the vaccine production market.

• Increased Investments in Healthcare Infrastructure

Increased investments in healthcare infrastructure and vaccine research and development are significantly bolstering the vaccine production market, making it a critical driver of growth. Governments and private entities are recognizing the importance of robust healthcare systems, especially following the global challenges posed by the COVID-19 pandemic. For instance, many countries are allocating more funding to upgrade laboratory facilities, invest in advanced manufacturing technologies, and train skilled personnel in vaccine production process. In addition, partnerships between governments and pharmaceutical companies foster innovation, allowing for faster development of new vaccines. Improved distribution networks ensure that vaccines can reach populations in a timely manner, particularly in underserved areas. This commitment to strengthening healthcare infrastructure enhances the capacity to produce vaccines and ensures better accessibility, ultimately contributing to improved public health outcomes and driving the overall growth of the vaccine production market.

Opportunities

• Emerging Infectious Diseases

The ongoing threat of new infectious diseases, such as emerging viruses and resistant pathogens, underscores the urgent need for rapid vaccine development and production. This environment creates significant market opportunities for pharmaceutical companies to innovate and expand their product portfolios. For instance, the COVID-19 pandemic highlighted the necessity for swift vaccine responses, prompting advancements in technologies like mRNA and viral vector platforms, which can be adapted for various pathogens. As new health threats continue to arise, companies are compelled to invest in research and development to create vaccines that are effective and can be rapidly deployed in response to outbreaks. This demand for agility and innovation allows firms to differentiate themselves in the market and contribute to global health security, ultimately positioning themselves as leaders in the ever-evolving landscape of vaccine production.

• Personalized Medicine and Targeted Therapies

The shift towards personalized medicine and targeted therapies presents a significant market opportunity in vaccine development, enabling the creation of tailored vaccines that address the specific health needs of various populations. This approach recognizes that genetic, environmental, and lifestyle factors can influence individual vaccine responses, prompting researchers to innovate and develop customized solutions. By focusing on specific demographics, such as age groups or individuals with certain health conditions, pharmaceutical companies can enhance vaccine efficacy and improve uptake rates. For instance, vaccines designed for immunocompromised patients or those with specific genetic markers are likely to yield better immune responses. Additionally, personalized vaccines can boost public confidence in immunization programs by demonstrating a commitment to addressing diverse health concerns. This innovation improves public health outcomes and positions companies as leaders in a rapidly evolving market.

Restraints/Challenges

• Development and Production Of Vaccines

The financial investment required for research, development, and production of vaccines is significant, often running into millions or even billions of dollars. This high cost encompasses various stages, including preclinical research, clinical trials, regulatory approvals, and manufacturing processes. Smaller companies frequently face challenges in securing adequate funding to support these extensive initiatives, which can limit their ability to innovate and bring new vaccines to market. In addition, without the financial backing that larger pharmaceutical firms possess, smaller entities may struggle to navigate the complex landscape of vaccine development effectively. This funding gap represents a critical challenge in the vaccine production market, as it can stifle competition and reduce the diversity of vaccine candidates available, ultimately hindering advancements in public health.

• Regulatory barriers and high entry costs

Regulatory barriers and high entry costs pose significant challenges for new companies attempting to enter the vaccine market, representing crucial market restraints. The vaccine development process is inherently complex, involving stringent regulations that require extensive clinical trials and thorough testing to ensure safety and efficacy. While these regulations are crucial for public health, they can create lengthy approval timelines, deterring smaller firms that may lack the necessary resources to navigate this landscape. In addition, the financial burden associated with research, development, and compliance can be prohibitive, especially for startups and smaller biotechnology firms. As a result, this environment limits competition within the market, reducing the diversity of innovative vaccine candidates.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Vaccine Production Market Scope

The market is segmented on the basis of classification ,and disease type. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Classification

• Adult Vaccine Production
• Pediatric Vaccine Production

 Disease Type

• Hepatitis B
• Malaria
• Yellow Fever
• Typhoid
• Rabies
• HIV
• Cancer
• Influenza
• West Nile
• Japanese Encephalitis
• Pneumococcal
• Rotavirus
• DTP (Diphtheria, Tetanus, Pertussis)
• Polio
• Varicella
• Meningococcal
• Measles
• Mumps
• Rubella
• Tuberculosis

Vaccine Production Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, classification, and disease type as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the vaccine production market, largely due to heightened public awareness regarding the dangers posed by infectious diseases. This growing consciousness has driven both government and private sector investments in vaccine production and distribution efforts. In addition, robust funding initiatives have further enhanced the accessibility and efficiency of vaccine deployment across the region.

Asia-Pacific region is projected to experience the fastest growth during the forecast period from 2024 to 2031, driven by a growing target population with significant unmet clinical needs. This increase in population is creating a higher demand for effective healthcare solutions, including vaccines. Consequently, the region's healthcare infrastructure is evolving to address these urgent demands, fostering substantial market expansion.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

疫苗生产市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的疫苗生产市场领导者是：

• 赛诺菲（法国）
• Valneva SE（法国）
• CSL有限公司（澳大利亚）
• 葛兰素史克公司 (英国)
• MassBiologics（美国）
• 强生私人有限公司（美国）
• 阿斯利康（英国）
• 辉瑞公司（美国）
• 默克集团（德国）
• 诺华公司（瑞士）
• 百特（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• IDT Biologika（美国）
• 赛默飞世尔科技公司（美国）
• 龙沙（瑞士）
• 勃林格殷格翰国际有限公司 (德国)
• Catalent, Inc（美国）
• Charles River Laboratories（美国）

疫苗生产市场的最新发展

• 2024 年 4 月，Bavarian Nordic A/S 宣布在美国推出唯一获得 FDA 批准的 mpox 疫苗 JYNNEOS。这一进展代表着提高疫苗可及性的关键一步，因为它为采购和分发创造了新的途径。此外，该计划还促进了公共和私人付款人的报销流程，确保有需要的人获得更广泛的覆盖。总体而言，此次扩展旨在改善公共卫生应对措施并提高全国范围内的 mpox 疫苗接种率
• 2024 年 10 月，葛兰素史克公司宣布与重庆智飞生物制品有限公司达成独家协议，共同在中国推广其带状疱疹疫苗 Shingrix，初始期限为三年。此次合作旨在提高该疫苗在中国市场的可用性和知名度。如果各方同意，合作有可能在初始期限之后延长。该协议凸显了葛兰素史克致力于扩大其在中国快速增长的疫苗市场的影响力，从而改善与带状疱疹相关的公共卫生结果

SKU-52923